Back to Journals » Drug Design, Development and Therapy » Volume 7

Advances with RNA interference in Alzheimer’s disease research

Authors Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W, Hu Z

Received 12 November 2012

Accepted for publication 11 December 2012

Published 22 February 2013 Volume 2013:7 Pages 117—125

DOI https://doi.org/10.2147/DDDT.S40229

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Shun Chen,1,2,* Xuemei Ge,2,* Yinghui Chen,3,* Nan Lv,2 Zhenguo Liu,1 Weien Yuan2

1Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, 2School of Pharmacy, Shanghai Jiaotong University, Shanghai, 3Department of Neurology, Jinshan Hospital, Fudan University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD.

Keywords: RNAi, β-amyloid, tau, amyloid precursor protein

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]